Of the 23 products we audited, four had every active ingredient at a dose supported by at least one RCT. The rest had real ingredients — just not enough of them to do anything.
This is not fraud. It is something subtler. Manufacturers list ingredients with genuine evidence, at doses that appear legitimate, but are consistently 30–80% below what the clinical trials actually used. The ingredient is real. The claim attached to it is technically defensible. The dose makes it inert. That gap is where the Indian brain supplement market lives.
How we looked at this
Twenty-three products. All purchased or verified on Amazon India between March and May 2026. Categories: branded "nootropic" stacks, "brain health" multivitamins, memory support supplements, and focus capsules. Price range: ₹499 to ₹2,400 per month's supply.
For each product, we pulled the full ingredient list and compared every active dose against what the clinical literature used. Where the evidence is a single small trial, we noted that. Where it is a meta-analysis of 10+ RCTs, we noted that too. The threshold for "clinically relevant dose" was simple: does this product match or exceed the dose used in the primary efficacy trial for this ingredient, for this endpoint?
The four that passed were, perhaps unsurprisingly, not the most heavily marketed. Two were plain single-ingredient products: AS-IT-IS Caffeine + L-Theanine (200mg caffeine, 200mg L-theanine, NABL COA, no ceremony) and Carbamide Forte L-Theanine 200mg. The third was a Bacopa monnieri product from Carbamide Forte with the standardisation and dose the cognitive trials actually used. The fourth was a standalone creatine monohydrate — not marketed as a brain product, but with the clearest cognitive evidence of anything in the category.
Everything else had problems. Not identical problems — they come in a few distinct patterns that are worth naming explicitly.
The four patterns brands use
Pattern 1: The correct ingredient, at a fraction of the dose
Bacopa monnieri has good cognitive evidence. The standard used in the strongest RCTs — Stough et al. (2001), Morgan and Stevens (2010) — is 300mg/day of extract standardised to 20–55% bacosides, for at least 12 weeks.1 That is specific. You need a certain extract grade, at a certain amount, for a certain period.
Seven of the 23 products we looked at contained Bacopa. Five of those seven listed doses between 50mg and 150mg — with no standardisation percentage disclosed. One listed 250mg of "Brahmi extract" with no bacoside content. One hit 300mg with standardisation specified. The other six are paying for the ingredient name, not the ingredient's function.
The same pattern shows up with Ashwagandha. The cognitive and stress RCTs that get cited use KSM-66 or Sensoril at 300–600mg/day, standardised to withanolide content. Of the 11 ashwagandha-containing brain products we looked at, four used generic root powder with no extract specification. Three used recognised extracts but at 125–200mg — half the minimum effective dose in the trials.2
Pattern 2: In-vitro evidence dressed as clinical evidence
Lion's Mane mushroom is genuinely interesting. The mechanism — stimulating nerve growth factor (NGF) via hericenones and erinacines — is real and well-studied in cell cultures and animal models. There is one small RCT in mild cognitive impairment (Mori et al., 2009, n=30) showing improvement on the Hasegawa Dementia Scale at 3g/day of dried mushroom powder.3 That is a single trial, modest sample size, specific population, specific dose.
In the Indian market, lion's mane appears in at least eight brain health products we audited. Doses range from 50mg to 500mg of extract. None specify the hericenone or erinacine content that drives the proposed mechanism. The Mori trial used 3,000mg of dried powder — much of which the brain products are providing as concentrated extract, but without specifying what concentration. The label says "Lion's Mane" and implies cognitive benefit. The research base is a single small RCT in a clinical population, with no replication as of May 2026.
This is not dishonest in the strict sense. Lion's mane has a plausible mechanism and at least some human data. But "the mechanism is real" and "this product dose will do something in a healthy 28-year-old in Bengaluru" are not the same claim, and the packaging tends to blur them.
Pattern 3: Proprietary blends hiding insufficient doses
Five products in our audit used a "cognitive blend" or "neuro matrix" format — listing the total weight of the blend without disclosing individual ingredient weights. This is legal under FSSAI labelling requirements as long as the blend is listed as a blend. It is also a reliable way to include 10 ingredients in amounts that sum to a meaningful total while each individual ingredient is present at a dose that does nothing.
Here is how the math works. Say a "Cognitive Performance Blend" weighs 600mg and contains ashwagandha extract, lion's mane, bacopa, ginkgo biloba, and phosphatidylserine. For each of those to be at its minimum effective dose, you would need roughly: ashwagandha 300mg + bacopa 300mg + ginkgo 120mg + lion's mane 500mg (as extract) + phosphatidylserine 100mg = at least 1,320mg in total. But the blend is only 600mg. Something is getting short-changed. You just cannot tell which, or by how much, because the label does not say.
If a product lists a "blend" weight and more than three active cognitive ingredients, assume at least half of them are below their clinical threshold. The math does not work otherwise. The only exception is if individual ingredient doses are disclosed separately — which defeats the purpose of calling it a blend, and which most brands avoid doing for exactly that reason.
Pattern 4: Vitamin B12 and B6 as the load-bearing evidence
This one is subtle. Several brain health products in India have a genuinely effective ingredient — methylcobalamin (B12) at 500–1000mcg, or P5P (activated B6) at meaningful doses — buried inside a formula that also includes 12 other ingredients at decorative amounts. The B12 is doing real work. The rest of the formula is scenery.
The product is not fraudulent — the B12 genuinely helps cognition in people with B12 deficiency, which in India describes a large fraction of the vegetarian population. But the product is sold as a "comprehensive nootropic stack" at ₹1,500/month when the effective part of it is the ₹200 B12 tablet sitting in the next aisle.
The ingredient list is real. The mechanism story is real. The doses are not real. That is the product.
Ingredient-by-ingredient: what the evidence says vs what products deliver
This is the table that matters. For each ingredient commonly found in Indian brain health products, the clinical threshold is the dose used in the study most likely to be cited on the product packaging. The "what Indian products deliver" column is the median dose across the products we audited that contained each ingredient.
| Ingredient | Clinical dose (primary trial) | Evidence quality | Median dose in Indian products | Gap |
|---|---|---|---|---|
| Bacopa monnieri 20–55% bacosides |
300mg/day × 12 weeks Stough et al., 2001 |
Multiple RCTs | 100mg (often unstandardised) | 67% below threshold |
| Ashwagandha KSM-66 or Sensoril |
300–600mg/day × 8 weeks Choudhary et al., 2017 |
Multiple RCTs, stress + cognition | 200mg (often generic extract) | 33–67% below threshold |
| Lion's Mane Hericium erinaceus |
3,000mg dried powder/day × 16 weeks Mori et al., 2009 |
1 RCT, MCI population, n=30 | 250mg extract (standardisation unknown) | Dose not comparable — extract concentration unknown |
| Ginkgo biloba GBE-761, 24% flavoglycosides |
120–240mg/day × 12+ weeks Oken et al., 1998 (meta) |
Moderate RCT base; effect size small | 80–120mg (often non-GBE extract) | At low end or below; extract grade rarely specified |
| L-Theanine | 100–200mg + caffeine 50–160mg Haskell et al., 2008 |
Consistent RCT support (with caffeine) | 100mg (often without paired caffeine) | Dose borderline; loses benefit without caffeine pairing |
| Phosphatidylserine | 100mg × 3/day (300mg total) × 12 weeks Crook et al., 1991 |
Older RCT base; mixed replication | 50–75mg | 50–75% below used dose |
| Vitamin B12 Methylcobalamin |
500–1000mcg/day (for deficiency correction) Multiple guidelines |
Strong — but only for deficient individuals | 500–1000mcg (usually correct) | Generally adequate. This is where most products' real benefit lives. |
| Creatine monohydrate | 5g/day × 6 weeks Rae et al., 2003 |
Multiple RCTs — strongest in vegetarians | 1–2g (when added to stacks) | 60–80% below threshold in stacks; correct only as standalone product |
| Rhodiola rosea 3% rosavins, 1% salidrosides |
400–600mg/day × 4–12 weeks Shevtsov et al., 2003 |
Small RCT base; stress/fatigue endpoint | 200–300mg (standardisation rarely disclosed) | 50% below threshold; extract grade key variable |
Three product autopsies
Rather than naming 23 products in a way that will be outdated in six months, it is more useful to walk through the three archetypes we found. If you pick up any brain health product in India and cannot slot it into one of these three types, contact us.
Archetype A: The credible single-ingredient or simple stack
Archetype B: The plausible multi-ingredient stack with underdosed actives
Archetype C: The proprietary blend — unknowable by design
Why this works on buyers
The products are not stupid. They are designed around a coherent insight: most buyers cannot easily verify doses against clinical trials, and the existence of a real ingredient with real evidence is enough to make the packaging feel credible. Bacopa monnieri has RCT support. Ashwagandha has RCT support. Those facts are true and they are on the label, implicitly.
What the buyer has to know additionally — that the dose matters as much as the ingredient, that extract standardisation makes a compound pharmacologically different from generic powder, that "blend" is a word that can hide anything — requires a level of engagement with the literature that most people reasonably do not have. The products exploit that gap cleanly.
There is also the placebo problem. Brain health is a domain where subjective improvement is easy to register and hard to attribute. You take a product for 30 days. You feel sharper on some days. You attribute it to the supplement. It might be the B12. It might be the fact that you are sleeping slightly better because you cut back on chai after 4pm. It might be that paying ₹1,200 for a brain supplement made you take your cognitive performance more seriously and you started reading more carefully. The supplement market in every country relies on this attribution ambiguity. India is not unique there.
A lot of Indian "brain health" buyers would get more benefit from correcting B12 and creatine deficiencies — both highly prevalent in vegetarians — than from any nootropic stack. That is not a supplement industry answer. It is just what the data says. A ₹350 methylcobalamin tablet plus a ₹500/month creatine habit beats every "cognitive complex" we audited for a vegetarian Indian adult on insufficient sleep.
What actually works — the short list
There are a handful of interventions with solid cognitive evidence at doses that are practical and affordable in India. None of them require a branded nootropic stack.
Caffeine + L-theanine (100–200mg each, paired). The most replicated acute cognitive intervention in the literature. Works for attention, reaction time, and working memory. Available cheaply from AS-IT-IS (NABL COA, ₹499/month) or simply from coffee plus Carbamide Forte L-Theanine. Strong RCT base
Creatine monohydrate (5g/day, plain monohydrate). Particularly relevant for vegetarians and sleep-deprived people. Cognitive benefit takes 4–8 weeks to develop. Available from GNC India (Creapure, ₹1,299/300g), AS-IT-IS (₹849/250g). Do not buy it as part of a stack — the doses in stacks are always too low. Multiple RCTs
Methylcobalamin B12 (500–1,000mcg/day) if deficient. Genuinely effective for cognition in the deficient population — which is a large fraction of Indian vegetarians. Test first. Boldfit 1,000mcg (₹349/90 tabs) is correctly dosed and honest. Strong evidence in deficient populations
Bacopa monnieri (300mg/day, 20%+ bacosides, minimum 12 weeks). The only herbal in the list with consistent cognitive RCT replication. Carbamide Forte Bacopa 300mg is the domestic benchmark — correct dose, standardisation specified, NABL COA published. The effect is slow. Do not expect anything in the first month. Multiple RCTs
Everything else — lion's mane, ginkgo, rhodiola, phosphatidylserine, all the adaptogens — has either weak human evidence, inconsistent replication, or is only effective in specific clinical populations. That does not mean they are useless. It means the confidence interval on their benefit is wide, the dose needs to be correct, and they are not what the products selling them typically deliver.
What to look for before you buy
Three questions, in order. If a product cannot answer all three, put it back.
1. Is every active ingredient's dose disclosed individually? Not a blend weight. Not "contains Bacopa monnieri extract." The milligrams per serving. If this information is not on the label or the product page, assume the dose is not something the brand wants you to calculate.
2. Is the extract specified? "Bacopa monnieri" and "Bacopa monnieri extract (20% bacosides)" are not the same compound in any pharmacologically meaningful sense. "Ashwagandha extract" and "KSM-66 ashwagandha root extract (5% withanolides)" are not the same. The extract grade is part of the dose — an unstandardised 300mg is not equivalent to a standardised 300mg.
3. Is there a batch COA? Not a certificate that says "manufactured in an ISO facility." A certificate of analysis for the specific batch you are buying, from a NABL-accredited lab, showing that the actual content matches the label. This is the minimum bar for purity verification. Brands that do this publish it. Brands that do not, do not.
Most brain health products in India fail at question one. Many fail at two. Almost all that fail one or two also fail three. That is useful information.
References
Disclosures: Naked Compound participates in the Amazon.in affiliate programme. Some links earn a small commission. No manufacturer provided samples or funding for this content. Product category analysis based on publicly available ingredient lists from Amazon India product pages, verified May 2026. Full policy: conflicts-policy